FDA Cites Blood Clot Risk in Birth Control Pills Containing Drospirenone, Updates Label

The Food and Drug Administration April 10 said it has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other pills.

The agency said it made this conclusion after reviewing recent observational studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. FDA said it is adding information about the studies to the labels of these birth control pills.

Drospirenone-containing oral contraceptives include Bayer’s Yasmin, Yaz, Beyaz, Safyral, and the generic equivalents for these products.

Revised Drug Labels.

The revised drug labels will report that some epidemiologic studies ...